Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Pillar Pacific Capital Management LLC

Pillar Pacific Capital Management LLC decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,218 shares of the biopharmaceutical company’s stock after selling 24 shares during the quarter. Pillar Pacific Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $4,453,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Cullen Frost Bankers Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 6.8% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 267 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 17 shares during the last quarter. IFP Advisors Inc increased its stake in Regeneron Pharmaceuticals by 11.7% during the 3rd quarter. IFP Advisors Inc now owns 181 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 19 shares during the period. Greenleaf Trust increased its stake in Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Greenleaf Trust now owns 1,184 shares of the biopharmaceutical company’s stock worth $663,000 after buying an additional 20 shares during the period. GAM Holding AG increased its position in shares of Regeneron Pharmaceuticals by 0.6% in the 3rd quarter. GAM Holding AG now owns 3,528 shares of the biopharmaceutical company’s stock worth $1,975,000 after purchasing an additional 21 shares during the last quarter. Finally, GFG Capital LLC increased its position in shares of Regeneron Pharmaceuticals by 1.9% in the 4th quarter. GFG Capital LLC now owns 1,126 shares of the biopharmaceutical company’s stock worth $544,000 after purchasing an additional 21 shares during the last quarter. 85.00% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ REGN traded down $7.76 during mid-day trading on Tuesday, hitting $452.82. The company’s stock had a trading volume of 40,295 shares, compared to its average volume of 1,092,396. The stock has a market cap of $48.51 billion, a price-to-earnings ratio of 16.83, a price-to-earnings-growth ratio of 0.82 and a beta of 0.30. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.89 and a quick ratio of 3.12. Regeneron Pharmaceuticals, Inc. has a one year low of $386.83 and a one year high of $664.64. The company’s fifty day simple moving average is $502.66 and its 200-day simple moving average is $542.45.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, February 4th. The biopharmaceutical company reported $9.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.11 by $2.42. The company had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.40 billion. Regeneron Pharmaceuticals had a net margin of 38.28% and a return on equity of 28.97%. The company’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter last year, the firm earned $7.50 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 27.23 EPS for the current year.

REGN has been the subject of several research reports. FIX raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and decreased their price target for the company from $635.00 to $575.00 in a report on Friday, January 8th. Credit Suisse Group boosted their target price on shares of Regeneron Pharmaceuticals from $753.00 to $760.00 and gave the company an “outperform” rating in a research note on Tuesday. Smith Barney Citigroup boosted their price target on shares of Regeneron Pharmaceuticals from $575.00 to $584.00 in a research report on Thursday, January 14th. Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $553.00 to $525.00 and set an “equal weight” rating on the stock in a report on Monday, February 8th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell boosted their target price on shares of Regeneron Pharmaceuticals from $575.00 to $584.00 and gave the stock a “buy” rating in a report on Thursday, January 14th. Six research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $616.82.

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Tuesday, December 1st. The shares were sold at an average price of $520.48, for a total value of $52,048.00. Following the sale, the director now directly owns 23,741 shares in the company, valued at approximately $12,356,715.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael S. Brown sold 2,480 shares of the stock in a transaction that occurred on Monday, January 25th. The shares were sold at an average price of $554.32, for a total transaction of $1,374,713.60. Following the completion of the sale, the director now owns 3,371 shares in the company, valued at $1,868,612.72. The disclosure for this sale can be found here. Company insiders own 11.84% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also: The Discount Rate – What You Need to Know

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.